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Daylight photodynamic therapy (DL-PDT), using short-
chained 5-aminolaevulinate (5-ALA) ester methylamino-
laevulinate (MAL), is an effective and well-tolerated 
treatment for actinic keratoses (AK) (1). Recently, there 
has been interest in the novel long-chained 5-ALA ester 
hexylaminolaevulinate (HAL), which has better skin 
penetration and can thus be used at low concentrations 
(2–4). This could be of economic value and reduce 
side-effects (5). We have reported previously that very 
low concentrations of HAL can be used with daylight 
activation (6). The current paper reports the long-term 
12-month outcome.
METHODS 
The methods are described in detail elsewhere (6). Volunteer 
patients with symmetrical actinic damage in the head area were re-
cruited and treated in June 2014. AKs were photographed, counted 
and marked on a plastic sheet, and 2 symmetrical equally graded 
(6) AKs, one on each treatment side, were biopsied bilaterally 
before treatment. A chemical sunscreen (P20®, SPF 20 Riemann 
& Co. A/S, Hilleroed, Denmark) was applied for 15 min, and the 
treatment areas were subsequently curet-
taged. Patients were randomized to re-
ceive DL-PDT with 0.2% HAL (Hexvix® 
powder, Photocure ASA, Oslo, Norway in 
Unguentum M, Allmiral, Madrid, Spain) 
on one side of the face or scalp and 16% 
MAL (Metvix, Galderma, Paris, France) 
on the other, both applied as a 0.025 mm2  
thick layer (treatment area mm2 * 0.25 
mg/mm2). Illumination was performed for 
2 h outdoors. Follow-up visits, including 
the mapping of the residual lesions and 
histological sampling, was conducted by 
the blinded investigator (MG). The histo-
logy (HE staining and p53 expression in 
average percentage of the 3 high power 
fields) of the samples was interpreted by 
a blinded pathologist (TTT). Wilcoxon 
signed-rank paired test was used for 
statistical analysis.
RESULTS
Of the 14 patients who completed 
the pilot trial, 13 were followed up 
for 12 months. One patient died 
before the 12-month follow-up 
due to reasons unrelated to the 
study. No residual lesions were treated between the 3- 
and 12-month follow-ups. Both treatments were nearly 
painless (visual analogue scale (VAS) ≤ 1). HAL caused 
milder adverse reactions, as assessed at 1 week (6).
At 12 months HAL DL-PDT resulted in similar sus-
tained lesion clearance compared with MAL (Fig. 1 and 
Table I). The mean lesion clearance per patient was 67% 
with HAL and 66% with MAL (p = 1.00). HAL was as 
effective as MAL in the treatment of grade I AKs, but a 
trend for lower clearance of grade II–III AKs was seen 
(Fig. 2 and Table I). One patient was excluded from 
the histological analysis because one biopsied lesion 
clinically taken as an AK appeared histologically to 
be seborrhoeic dermatitis. Histological clearance was 
equal for both photosensitizers (Table I). At 12 months, 
42% of the HAL-treated and 50% of the MAL-treated 
biopsied lesions were completely histologically cleared 
(p = 0.688). Compared with baseline, the mean expres-
sion of p53 was reduced by 20% in the HAL group and 
by 51% in the MAL group (p = 0.123).
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Fig. 1. Complete clearance of actinic keratoses after daylight photodynamic therapy with 
hexylaminolaevulinate (HAL) (left side, a and c) and with methylaminolaevulinate (MAL) (right side, 
b and d). (a) and (b) before treatment; (c) and (d) 12 months after treatment.
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DISCUSSION
Previously, HAL has been studied at very low 0.1% con-
centrations for the prevention of cutaneous squamous 
carcinoma in mice (7). HAL-induced protoporphyrin IX 
(PpIX) fluorescence has been reported in several studies 
and it has been shown that HAL has great potential when 
used at low concentrations (8–11). We reported a 3-month 
mean per-patient lesion clearance of 73.4% with HAL 
and 77.8% with MAL (6), which is in concordance with 
previous DL-PDT studies (1). Long-term clearance is ra-
rely reported in DL-PDT studies. Recently, 62% and 87% 
mean per-patient lesion clearance was reported for MAL 
and amino-5-laeuvulinate nanoemulsion (BF-200 ALA) 
(12). In our current study at 12 months the clearances were 
67% for HAL and 66% for MAL, which supports the pre-
vious 12-month data with MAL. Our results show similar 
efficacies for HAL and MAL in the long-term follow-up. 
A limitation of our pilot study was the small sample 
size. As lower clearance was seen with thicker grade II–III 
lesions, low-concentration HAL should only be used for 
thin AKs. The fact that p53 expression was less reduced 
in the HAL group may indicate poorer reversal in the car-
cinogenetic process. However, over a long period, there 
was also sustained clearance of AKs in the HAL group.
Our results show that low concentrations of HAL can 
be used in the treatment of thin AKs and this clearance 
was maintained in a long-term follow-up. The use of 
HAL at very low doses could lead to significant reduc-
tions in treatment costs.
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Table I. Baseline characteristics, clinical and histological clearance 
rates at 12 months
HAL MAL p-values
Clinical
Baseline 
  Total number of lesions 95 88 0.695
    Grade I lesions 71 67 0.711
    Grade II–III lesions 24 21 0.625
  Lesions/patient, mean (range) 7.3 (3–14) 6.8 (3–10)
12 months 
  Complete response all 
   (mean) % per patient)
66.5 65.9 1.000
  Grade I 76.2 63.1 0.285
  Grade II–III 44.4 78.7 0.156
  New lesions 3 1 0.625
Histological
Baseline biopsied lesions 12 12
  Grade I 2 4 0.625
  Grade II–III 10 8 0.625
  p53, mean (%) 37.6 37.4 0.791
12 months
 Complete response, % 41.6 50 0.688
 Mean reduction in p53 expression, % 20 51 0.123
HAL: hexylaminolaevulinate; MAL: methylaminolaevulinate.
Fig. 2. Mean per patient (half-face) lesion clearance (%) at 12 
months. HAL: hexylaminolaevulinate; MAL: methylaminolaevulinate; 
AK: actinic keratoses.
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